AfterRaise/Companies/Breakthru Medicine

Breakthru Medicine

Breakthru Medicine is an oncology company developing therapies for solid cancers. From its funding announcement.

$60M Series ARaised 9 months agoPhoenix, USABiotech & PharmaUSA

In their own words

What Breakthru Medicine says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "oncology company developing therapies for solid cancers". Source

Market expansion

Public signal Read from the company's own description of what the funding supports.

Why now

Where Breakthru Medicine is today

Breakthru Medicine announced a Series A round of $60M on 29 January 2026.

Latest round
Series A
Amount
$60M
Announced
29 January 2026
Headquarters
Phoenix, USA
Sector
Biotech & Pharma
Investors
Not stated
Also participating
Dave Morehead, Fred Eshelman, Mark Gergen
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

43
Established
0 funding signals in the last 90 days
Funding recency
9/40
announced within the last year
Round scale
19/25
round size relative to the market
Funding stage
15/20
Series A
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 29 January 2026
    $60M Series A
    Investors not stated in the announcement.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • New market entry
  • First local hires in the new market
  • Local entity and legal setup
  • Accelerated hiring across functions

Opportunities this could create

  • Licensing and BD partnerships
  • Market-entry advisers
  • Local employment infrastructure
  • In-market partnerships
  • Clinical operations

Based on the Biotech & Pharma sector, a Series A round and the priorities the company itself set out. Not a statement of fact.

Early momentum2 connected signals
  • 29 January 2026$60M Series A announced
  • 29 January 2026Stated priority: market expansion

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Breakthru Medicine is open to

Not yet specified

Breakthru Medicine has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Breakthru Medicine

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Breakthru Medicine?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: your website, the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector